Sun, Apr 20, 2014, 4:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • cyrusabdinh cyrusabdinh Jan 28, 2013 12:57 PM Flag

    Listing of Company Developments

    NeoStem Announces Further Expansion of Intellectual Property Coverage
    NeoStem Announces Receipt of Hellman Research Award by Academic Collaborator
    NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into Cell Therapy Manufacturing
    01/09 NeoStem Announces Research Supporting VSEL(TM) Technology Presented at the
    01/07 NeoStem's Subsidiary, Progenitor Cell Therapy, and Hackensack University Medical..
    01/02 NeoStem to Present at Multiple Conferences in January
    2012 NeoStem to Present at Multiple Conferences in December
    2012 NeoStem to Present at Piper Jaffray 24th Annual Healthcare Conference
    2012 NeoStem Receives Notification of $1.2 million NIH Grant Award for First Clinical
    2012 NeoStem Ranked Number 1 Fastest Growing Company in the Tri-State Region on Deloitte
    2012 NeoStem Announces Quarterly Results and Business Update
    2012 NeoStem to Present at Multiple Conferences in November
    2012 NeoStem Announces the Redemption of the Outstanding 7% Series E Preferred Stock
    2012 NeoStem Announces New Publication That Supports Positive Results of AMR-001
    2012 NeoStem Announces Very Small Embryonic-Like Cells (VSELTM) Publication
    2012 NeoStem’s CEO Robin Smith Gives ‘The Stock Radio’ an Update on the Company
    2012 NeoStem to Present at Multiple Conferences in October
    2012 NeoStem to Present at Noble Capital Markets’ Life Sciences Exposition on September
    2012 Progenitor Cell Therapy, a NeoStem Company, Invited to Present at Two Conferences

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBS
6.46-0.20(-3.00%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.